In patients with PH and HF with reduced EF, both acute [112,113,114] and chronic [115,116,117] oral PDE5 inhibition therapy was well tolerated and consistently decreased pulmonary artery systolic pressure and pulmonary vascular resistance without substantial changes in systemic blood pressure. This evidence concerns the gene PDE5A and hydrops fetalis.